NeuroMetrix Rceives GSK 'Bridge' For Quell Wearable Pain-Relief Development
Executive Summary
Recent modifications accelerated portion of milestones remaining in firms' agreement over the next 12 months, reduced GSK's aggregate amount payable and forwarded $2m to NeuroMetrix. Firms are co-funding future development of Quell technology and additional TENS products for chronic pain beginning in 2019.
You may also be interested in...
GSK Consumer Tries On Wearable Pain Relief With NeuroMetrix Deal
GSK Consumer purchases ex-US rights to pain relief device Quell from NeuroMetrix in a deal that includes co-development of transcutaneous electrical nerve stimulation products.
Homeopathics, Supplements, OTC Medicines Overlap In Pharmacists’ ‘Over-The-Counter’ Survey
Results of U.S. News & World Report’s first “Best OTC Medicine & Health Products” survey include homeopathic formulations, supplements and non-drug topicals in same categories of indications with nonprescription pharmaceuticals.
NMN Supplement Firm Works On Disclosing Sales Relationships With Advertising Affiliates
Renue By Science agrees with National Advertising Division recommendations to “clearly and conspicuously disclose” material connections in online advertising by employees, nonprofits and others offering sales to its supplements containing nicotinamide mononucleotide, quercetin or resveratrol.